Erasca (ERAS) Income from Continuing Operations (2020 - 2026)
Erasca's (ERAS) quarterly Income from Continuing Operations came in at 860697000.0 in Q1 2026, down 2218.06% YoY from 40636032.65 in Q1 2025, and down 2423.74% on a QoQ basis from 34104000.0 in Q4 2025.
Powered by 
Analysis
Erasca (ERAS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Income from Continuing Operations data on file, last reported at 860697000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 2218.06% year-over-year to 860697000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1001618000.0 (down 267.67% YoY) and the FY2025 annual result came in at 383105000.0, down 98.94% from the prior year.
- Income from Continuing Operations retreated to 860697000.0 in Q1 2026, from 34104000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 29401000.0 in Q4 2023 to a low of 860697000.0 in Q1 2026.
- A 5-year average of 118289470.59 and a median of 55740000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 78.8% — and 2026, when it slumped 2218.06%.
- Tracing ERAS's Income from Continuing Operations over 5 years: stood at 138693000.0 in 2022, then surged by 78.8% to 29401000.0 in 2023, then dropped by 27.25% to 37412000.0 in 2024, then advanced by 8.84% to 34104000.0 in 2025, then tumbled by 2423.74% to 860697000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 860697000.0 (Q1 2026), 34104000.0 (Q4 2025), and 51077000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.45 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.47 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.86 Bn | 52.72 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.14 Bn | 44.14 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.20 Bn | 31.89 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Erasca | 5.00 Bn | 5.00 Bn | - | -44.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.08 Mn |
| Mar 31, 2026 | -183.46 Mn |
| Dec 31, 2025 | -29.04 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -30.43 Mn |
| Sep 30, 2024 | -31.37 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.97 Mn |
| Sep 30, 2021 | -46.07 Mn |